Colorado-based DaVita HealthCare Partners’ dialysis division has entered into a joint venture (JV) agreement with Xiaoyi Zhang, president of Shunjing Renal Hospital to establish a kidney care speciality hospital chain in the Shandong province of China.
The agreement establishes DaVita (Shandong) Kidney Disease Hospital as a first-of-its-kind renal dialysis JV between a multinational healthcare provider and the private sector in China.
Shunjing Renal Hospital is the only facility in Shandong province’s capital of Jinan that is approved for dialysis services.
DaVita international operations CEO Dennis Kogod said: "DaVita has the potential to significantly raise the quality of kidney care services available in this region of China.
"The new hospital chain we are creating is a major step in that direction."
Zhang, who will be the CEO of DaVita (Shandong) Kidney Disease Hospital, said: "We will incorporate DaVita’s advanced concepts and technologies in healthcare management with our experience in operating hospitals in the local market.
"This is a win-win for end-stage renal disease patients as we build a Sino-US joint venture flagship hospital starting in Jinan City and eventually across Shandong province."
Recent studies showed that the number of people living with chronic kidney disease (CKD) in China could be as many as 120 million, and that only 12% of these are aware of their condition.
DaVita Asia-Pacific region president Atul Mathur said: "Chronic kidney disease is a growing health issue in China.
"DaVita [Shandong] Kidney Disease Hospital directly addresses this problem. By expanding services available, we’ll be helping many patients to live better quality lives."
In August, DaVita HealthCare Partners signed a $415m deal to acquire US-based Renal Ventures, an operator of 36 dialysis clinics in six states.
The company’s divisions, including Multispecialty Physician Partners and Physician Venture Partners, operate infusion and vascular centres in three states.